Abstract |
In recent decades, the interest in metallodrugs as therapeutic agents has increased. Casiopeinas are copper-based compounds that have been evaluated in several tumor cell lines. Currently, casiopeina III-ia ( CasIII-ia) is being evaluated in phase I clinical trials. The aim of the present work is to develop a niosome formulation containing CasIII-ia for intravenous administration through a quality-by-design (QbD) approach. Risk analysis was performed to identify the factors that may have an impact on CasIII-ia encapsulation. The developed nanoformulation optimized from the experimental design was characterized by spectroscopy, thermal analysis, and electronic microscopy. In vitro drug release showed a burst effect followed by a diffusion-dependent process. The niosomes showed physical stability for at least three months at 37 °C and 75% relative humidity. The in vitro test showed activity of the encapsulated CasIII-ia on a metastatic breast cancer cell line and the in vivo test of nanoencapsulated CasIII-ia maintained the activity of the free compound, but showed a diminished toxicity. Therefore, the optimal conditions obtained by QbD may improve the scaling-up process.
|
Authors | Zenayda Aguilar-Jiménez, Mauricio González-Ballesteros, Silvia G Dávila-Manzanilla, Adrián Espinoza-Guillén, Lena Ruiz-Azuara |
Journal | International journal of molecular sciences
(Int J Mol Sci)
Vol. 23
Issue 21
(Oct 22 2022)
ISSN: 1422-0067 [Electronic] Switzerland |
PMID | 36361549
(Publication Type: Journal Article)
|
Chemical References |
- (4,4-dimethyl-2,2-bipyridine)(acetylacetonate)copper(II)
- Copper
- Organometallic Compounds
- Antineoplastic Agents
- Liposomes
|
Topics |
- Copper
(chemistry)
- Organometallic Compounds
(chemistry)
- Antineoplastic Agents
(pharmacology)
- Cell Line, Tumor
- Liposomes
|